Abstract
Background/AimsThis study evaluated and compared the clinical and prognostic values of the grading criteria used by the World Health Organization (WHO) and the European Neuroendocrine Tumors Society (ENETS). Moreover, this work assessed the current best prognostic model for colorectal neuroendocrine tumors (CRNETs).ResultsThe 2010 WHO classifications and the ENETS systems can both stratify the patients into prognostic groups, although the 2010 WHO criteria is more applicable to CRNET patients. Along with tumor location, the 2010 WHO criteria are important independent prognostic parameters for CRNETs in both univariate and multivariate analyses through Cox regression (P<0.05).MethodsData from 192 consecutive patients histopathologically diagnosed with CRNETs and had undergone surgical resection from January 2009 to May 2016 in a single center were retrospectively analyzed.ConclusionsFindings suggest that the WHO classifications are superior over the ENETS classification system in predicting the prognosis of CRNETs. Additionally, the WHO classifications can be widely used in clinical practice.
Highlights
Colorectal neuroendocrine tumors (CRNETs) are a group of heterogeneous neoplasms traditionally referring to carcinoid tumors [1,2,3]
Findings suggest that the World Health Organization (WHO) classifications are superior over the European Neuroendocrine Tumor Society (ENETS) classification system in predicting the prognosis of CRNETs
The WHO classifications can be widely used in clinical practice
Summary
Colorectal neuroendocrine tumors (CRNETs) are a group of heterogeneous neoplasms traditionally referring to carcinoid tumors [1,2,3]. The annual incidence of rectal neuroendocrine tumors (NET) is approximately 0.86/100,000. CRNETs are heterogeneous and rare, and their stratification into different prognostic groups has been hindered by the lack of a unified staging system; NET has been evolving for more than a century already [8,9]. The European Neuroendocrine Tumor Society (ENETS) proposed a tumor-node-metastasis www.impactjournals.com/oncotarget (TNM) staging system in 2006 [15,16]. The prognostic significance and the stage-specific survivals according to ENETS TNM staging systems have been confirmed by some studies [17,18,19]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
